Clinical trials: Gastric (Stomach) Cancer
Gastric Cancer
Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer
Surgery is the first standard treatment for stomach cancer, but it still has negative factors such as bleeding, leakage, closure, surgery part infection and cardiovascular and lung complication by general anesthesia.
- Trial name
- NCT01971775
- Testing
- Ultrasonically activated Shears, Conventional Monopolar Electrocautery
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Seoul National University Hospital
Gastric Cancer
A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
Chemotherapy, immune checkpoint inhibitors, and anti-angiogenic targeted therapies have been explored in combination for neoadjuvant and conversion therapies.
- Trial name
- NCT06464601
- Testing
- fruquintinib combined with immune checkpoint inhibitors and chemotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Wuhan University
Gastric Cancer (GC), Premalignant Lesion
AI-Based Risk Prediction Model for Upper Digestive Tract Cancer
Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development.
- Conditions
- Gastric Cancer (GC), Premalignant Lesion, Gastric Intestinal Metaplasia, Atrophic Gastritis
- Trial name
- NCT07605312
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast), Malignant Ascites
Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
The study will be performed to obtain further efficacy and safety data in order to obtain a marketing authorization (pivotal study). In addition, health economic data are to be collected.
- Trial name
- NCT00836654
- Testing
- Catumaxomab (Removab), paracentesis
- Volunteers
- 258 people
- Sponsor
- Neovii Biotech
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
- Conditions
- Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT07021066
- Testing
- BL-M05D1
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- SystImmune Inc.
GastroEsophageal Cancer
GastrOesophageal Tumor, Immune Microenvionnment (GOTIM)
This trial is a prospective, monocentric, non-therapeutic, interventional cohort study aiming to decipher the immune TME through standard neoadjuvant CT in resectable G/GEJ adenocarcinomas.
- Trial name
- GOTIM (NCT05644431)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Leon Berard
Gastric Cancer
Research on Early Recurrence of Locally Advanced Gastric Cancer Based on CT Radiomics Prediction
This study aims to develop a model for predicting postoperative recurrence in patients with LAGC using artificial intelligence (AI) technology based on preoperative computed tomography (CT) images
- Trial name
- LAGC (NCT07683195)
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Liu Yang
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach
The purpose of this study is to determine the rate of complete pathological responses (percentage of patients with pCR referring to the total number of enrolled and eligible patients), as evaluated centrally by a reference…
- Trial name
- HerFLOT (NCT01472029)
- Testing
- 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab, Post-operative treatment trastuzumab mono therapy
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- AIO-Studien-gGmbH
Gastric Cancer
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
This is a phase I, multi-center clinical trial to evaluate the safety, tolerability, antitumor activities and pharmacokinetics of IN10018 as monotherapy or in combination with docetaxel in previously-treated locally advanced or…
- Trial name
- NCT05327231
- Testing
- IN10018, Docetaxel
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma (Siewert II-III)
Molecular Characterization of Tumor-Microenvironment Interactions to Predict Drug Resistance in Gastric and GEJ Adenocarcinoma
Surgical resection remains the only curative option for resectable gastric cancer, but perioperative FLOT chemotherapy is associated with substantial rates of chemoresistance and recurrence, largely driven by marked tumor…
- Trial name
- GASTROIMMUNE (NCT07692477)
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
This study will evaluate the efficacy and safety of intravenous RC48-ADC in local advanced or metastatic gastric patients with the overexpression of HER2.
- Trial name
- NCT03556345
- Testing
- RC48-ADC
- Where
- China
- Volunteers
- 127 people
- Sponsor
- RemeGen Co., Ltd.
Gastric Cancer Stage III
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
The goal of this randomized, controlled phase III clinical trial is to evaluate whether combining Tislelizumab with standard SOX chemotherapy improves disease-free survival (DFS) compared to chemotherapy alone in patients with…
- Trial name
- NCT06939439
- Testing
- Tislelizumab + SOX Chemotherapy, SOX Chemotherapy
- Where
- China
- Volunteers
- 416 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Cancer
Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
The purpose of the study is to verify non-inferiority of survival time between Isovorin/5-fluorouracil (1-LV/5FU) therapy and TS-1 therapy in patients with inoperable advanced or recurrent gastric cancer.
- Trial name
- NCT00195572
- Testing
- Isovorin, TS-1
- Where
- 43 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pancreatic Neoplasms, Stomach Neoplasms
Robotic vs Laparoscopic and Open Surgery for Abdominopelvic Cancers
Robotic surgery has become an increasingly common option for treating cancers in the abdomen and pelvis. However, whether robotic surgery leads to better cancer-related outcomes than laparoscopic (keyhole) surgery or open surgery…
- Conditions
- Pancreatic Neoplasms, Stomach Neoplasms, Rectal Neoplasms, Uterine Cervical Neoplasms
- Trial name
- NCT07821775
- Testing
- No Intervention: Observational Cohort
- Where
- South Korea
- Volunteers
- 32,949 people
- Sponsor
- Asan Medical Center
Overall Response Rate
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients
- Trial name
- NCT06277024
- Testing
- Combination of Cardonizumab with Lenvatinib and SOX regimen
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University
Stomach Neoplasms
Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma
Preclinical studies at our institution, based on a genetic mouse model of stomach cancer, strongly suggest that innervation of the stomach wall is deeply involved in tumorigenesis of stomach cancer.
- Trial name
- NCT01821196
- Testing
- biopsy
- Sponsor
- St. Olavs Hospital
Oesophageal Cancer, Gastric Cancer
Prehabilitation Via a Mobile Application in Oesophago-gastric Cancer
The overall aim of this study is to assess the feasibility of a mHealth prehabilitation programme delivered via a mobile app for people with oesophago-gastric cancer by evaluating its user satisfaction and acceptance.
- Conditions
- Oesophageal Cancer, Gastric Cancer, Prehabilitation, mHealth Application
- Trial name
- NCT06046846
- Testing
- Asensei app
- Volunteers
- 20 people
- Sponsor
- Queen Margaret University
Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of Apatinib plus Camrelizumab combined with docetaxel and S-1 as the first-line treatment of metastatic adenocarcinoma of gastric and gastroesophageal junction.
- Trial name
- NCT04781686
- Testing
- Camrelizumab, Apatinib Mesylate, S1
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhou Fuxiang
Pancreatic Cancer, Gastric Cancer
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person.
- Conditions
- Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer
- Trial name
- NCT03190941
- Testing
- Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
The main purpose of this observational study with Docetaxel is to determine the number of treatment cycles and the quantity of Doce onkovis needed therefore under the special circumstance of ambulant chemotherapy.
- Trial name
- NCT01614002
- Where
- 23 sites in Germany
- Volunteers
- 371 people
- Sponsor
- Onkovis GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.